Vynfinit: Withdrawal of the marketing authorisation application


On 16 May 2014 Endocyte Europe B.V. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it has decided to withdraw its application for a marketing authorisation for Vynfinit, for the treatment of ovarian cancer which has become resistant to platinum-based cancer treatment.

Key facts

Product number
Date of withdrawal
Company making the application
Endocyte Europe, B.V.
Withdrawal type
Initial authorisation

Related information on withdrawals

A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

How useful was this page?

Add your rating